Variation in the human TP53 gene affects old age survival and cancer mortality

Authors :: van Heemst, D
Mooijaart, S P
Beekman, M
Schreuder, J
de, Craen AJ
Brandt, B W
Slagboom, P E
Westendorp, R G
group, Long Life study
Preventive Dentistry
Source :: van Heemst, D, Mooijaart, S P, Beekman, M, Schreuder, J, de, C AJ, Brandt, B W, Slagboom, P E, Westendorp, R G & group, L L S 2005, ' Variation in the human TP53 gene affects old age survival and cancer mortality. ', Experimental Gerontology . https://doi.org/10.1016/j.exger.2004.10.001, Experimental Gerontology. Elsevier Inc.
Publication Year :: 2005
Publisher :: Elsevier Inc., 2005.
Abstract: Longevity may depend on a balance between tumor suppression and tissue renewal mechanisms [Campisi, J., 2003. Cancer and ageing: rival demons? Nat. Rev. Cancer 3 (5), 339-349]. Mice with constitutively activated p53 are almost cancer free but their life span is reduced and accompanied by early tissue atrophy [Tyner et al., 2002. p53 mutant mice that display early ageing-associated phenotypes. Nature 415 (6867) 45-53]. Replacement of arginine (Arg) by proline (Pro) at position 72 of human p53 decreases its apoptotic potential [Dumont et al., 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33 (3), 357-365] providing a tool to test for a similar trade-off in humans. Using a formal meta-analysis of the published literature we show that carriers of the TP53 codon 72 Pro/Pro genotype have an increased cancer risk compared to Arg/Arg carriers (p

Tools